SCHEMBL20436600

SCHEMBL20436600

CC(=O)c1cccc(CO[Si](C)(C)C(C)(C)C)c1F

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.43
MRGPRX4 Q96LA9 10/20 0.39
SGMS2 Q8NHU3 1/20 0.35
KAT6A Q92794 1/20 0.34
KMT2A Q03164 1/20 0.34
MAOB P27338 2/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33
PDK3 Q15120 1/20 0.33
PDK4 Q16654 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TACR1 P25103 1/20 0.33
MAOA P21397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29100989 0.86 MRGPRX4 (0.50) BACE1MRGPRX4KMT2AKDM4EALDH1A1
SCHEMBL30630386 0.86 MRGPRX4 (0.50) BACE1MRGPRX4KMT2AKDM4EALDH1A1
SCHEMBL25201867 0.85 BACE1 (0.41) BACE1MRGPRX4SGMS2KAT6AMAPT
SCHEMBL20436602 0.82 BACE1 (0.38) BACE1MRGPRX4KAT6A
SCHEMBL15000653 0.80 BACE1 (0.43) BACE1TACR1
SCHEMBL3076782 0.79 BACE1 (0.40) BACE1KMT2AMAOB
SCHEMBL15000893 0.78 CYP4F2 (0.45) BACE1
SCHEMBL31658767 0.78 MAOB (0.40) BACE1SGMS2MAOBMAPTHPGD
SCHEMBL29995380 0.77 BACE1 (0.39) BACE1TACR1
SCHEMBL29101037 0.77 BACE1 (0.39) BACE1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2022-05-12 US disclosed
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. 2021-07-27 US disclosed
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2021-04-08 US disclosed
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. (US) 2019-09-03 US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 BACE1 4667/4885MRGPRX4 163/4885SGMS2 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.